Search

874 Result(s)
Sort by

BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Shanghai

Shanghai

Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Lyon

Lyon

The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Careers

Careers

Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
emperor-preserved-heart-failure-full-data

emperor-preserved-heart-failure-full-data

Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
AMR_Action_Fund

AMR_Action_Fund

Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Lung Cancer

Lung Cancer

Find out more about lung cancer, the second most common cancer worldwide, that claims more lives each year than any other type.
Partnership-with-clicktherapeutics

Partnership-with-clicktherapeutics

Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
Mareks Disease Poultry Chicken

Mareks Disease Poultry Chicken

Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
Our Expectations

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
EFPIA Mission Possible

EFPIA Mission Possible

This new video highlights how treatments once known for type 2 diabetes are now helping to prevent heart failure, stroke or kidney disease.
Collaboration-with-OxfordBioTherapeutics

Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Connect with your heart

Connect with your heart

If you know someone who has #type2diabetes, they are twice as likely to develop heart failure than those without.
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.